European Neuropsychopharmacology (v.21, #S2)
P.5.001 Difference in lesions induced by unilateral administration of 6-hydroxydopamine into the left and right substantia nigra pars compacta by E. Ivanova; I. Kokshenev; I. Kapitsa; T. Voronina (S154).
P.5.002 Natalizumab reduces apathy in relapsing-remitting multiple sclerosis patients by R. Berkovich (S154-S155).
P.4.017 Antihypoxic and enzyme inhibitory activity of the new anxiolytic drug afobazol by K.N. Koliasnikova; T.Y. Mozhaeva; G.A. Nazarova; N.N. Zolotov (S153-S154).
P.4.016 Comparative study of afobazol and diazepam behavioural effects in pentylenetetrazole-induced anxiety model in Wistar rats by A. Volkova; A. Shimshirt; T. Kalinina; T. Voronina (S153).
P.4.014 Afobazol differently modulates monoamine levels in the brain structures of C57BL/6 and BALB/C mice after serotonin depletion induced by PCPA by P. Klodt; V.B. Narkevich; V.S. Rogovsky; V.S. Kudrin; K.S. Rayevsky (S152).
P.4.015 The interlinear effects of the combined injection of afobazol and selective antagonists of serotonin (5-HT) receptors: a behavioural study by V.B. Narkevich; E.V. Shubenina; A.I. Davydova; V.S. Kudrin; K.S. Rayevsky (S152-S153).
P.5.003 Pharmacokinetics of himantane in rabbits by E.A. Litvin; P.O. Bochkov; D.V. Bastrygin; V.P. Zherdev; M.I. Emeljanov (S155).
P.5.004 Neuroprotective effect of proline-containing dipeptide, noopept on PC12 neuronal cells by M.K. Salimgareeva; U.S. Fatkullina; L.F. Zainullina; J.V. Vakhitova; R.U. Ostrovskaya; S.B. Seredenin (S155-S156).
P.5.009 Behavioural and biochemical effects of a novel dipeptide mimetic of nerve growth factor on a model of incomplete global ischemia in rats by P. Povarnina; S.V. Nikolaev; T.A. Antipova; T.A. Gudasheva (S158-S159).
P.5.010 The behavioural and neurochemical effects of NGF dipeptide fragment GK-2 in MPTP-lesioned C57BL mice by A.V. Ponomarev; P.M. Klodt; V.B. Narkevich; V.S. Kudrin; P.Y. Povarnina; T.A. Gudasheva (S159).
P.5.008 Prevalence of dementia in St. Petersburg and Leningrad Region (Russian Federation), 2000–2004 by S. Sluchevskaya; N. Semenova (S158).
P.5.007 Effect of nanosomic erythropoietin in rats with intracerebral post-traumatic haematoma (hemorrhagic stroke) by I.N. Solev; O.S. Elizarova; V.Y. Balabanyan; S.A. Litvinova; T.L. Garibova; T.A. Voronina (S157-S158).
P.5.005 Effects of a novel neuroprotective calcium salt of N-(5-hydroxy-nicotinoyl)-L-glutamate in a model of Alzheimer's disease and in aging rodents by A. Kiselev; S.V. Stovbun; V.I. Sergienko (S156).
P.5.006 Piracetam treatment and cognitive performance of patients with mild cognitive impairment by A. Borkowska; M. Ziolkowska-Kochan; A. Kalwa; W. Drozdz (S157).
P.4.013 Effect of peripheral administration of peptide ligands of opioid receptors on anxiety and locomotor activity in rats by G.A. Nazarova; K.N. Koliasnikova; A.A. Kolpakov (S151-S152).
P.4.012 Study of the structure-anxiolytic activity relationship among new pyrrolo[1,2-a]pyrazine derivatives by G.V. Mokrov; A.M. Likhosherstov; G.M. Molodavkin; T.A. Gudasheva (S151).
P.4.003 Thermotropic liquid crystal - potential enhancer of transdermal delivery of 1.4-benzodiazepines by I.A. Kravchenko; Y.A. Boyko; N.A. Novikova (S146).
P.4.004 Dipeptide anxiolytic GB-115: new receptor targets by L. Kolik; T.A. Gudasheva; S.B. Seredenin (S146-S147).
P.4.002 Anxiogenic or anxiolytic effects of nociception analogue are dose-dependent and sex-specific by E. Ivanova; N.Y. Sarycheva; V.A. Dubynin; V.N. Kalikhevich; Z.A. Ardemasova; A.A. Kamensky (S145-S146).
P.4.001 Influence of single and chronic intranasal injections of the arginine-vasopressin fragment Ac-D-MPRG on the ontogeny of the behavioural reactions in white rats by O. Voskresenskaya; A.A. Kamensky; V.P. Golubovich (S145).
P.3.004 Family-based association study of glycogen synthase kinase 3 (GSK3)-beta gene polymorphism in schizophrenia by M. Skibinska; P. Kapelski; J. Hauser (S143-S144).
P.3.005 Dilept - a novel type of antipsychotic based on neurotensin by R.U. Ostrovskaya; T.A. Gudasheva; S.B. Seredenin (S144-S145).
P.4.005 Anxiolytic profile of 5-HT3-antagonist RU 1204 versus tropisetron and diazepam by D. Yakovlev; N. Kolobrodova; A. Spasov; V. Anisimova (S147).
P.4.006 The bioavailability of afobazol and compound M-11 in rats by D.V. Bastrygin; A.O. Viglinskaya; P.O. Bochkov; M.I. Emeljanov; Y.G. Novitskaya; O.G. Pronina; V.P. Zherdev (S147-S148).
P.4.010 Considerably different mechanisms underlie the effects of the ACTH(4–10) analogue semax on stress-induced analgesia and stress-induced behaviour by D. Manchenko; D. Vilensky; N. Levitskaya; A. Kamensky; N. Myasoedov (S150).
P.4.011 Analogues of cyclo-L-prolylglycine and their anxiolytic, nootropic and antihypoxic activity by K.N. Koliasnikova; G.A. Nazarova; M.A. Konstantinopolskiy; T.A. Gudasheva (S150-S151).
P.4.009 Afobazol as inhibitor of NRH: quinone reductase 2 enzyme by I. Kadnikov; M. Voronin; S. Seredenin (S149-S150).
P.4.008 Effect of opiate system blockade on the anxiolytic effects of a benzodiazepine tranquillizer in inbred mice with active versus passive stress response by A.V. Nadorova; M.M. Kozlovskaya; L.G. Kolik; S.B. Seredenin (S149).
P.4.007 The effect of changes in the brain opioid system activity on the adaptive behavior of BALB/c and C57BL/6 mice by A.V. Nadorova; I.I. Kozlovskiy; M.M. Kozlovskaya (S148).
P.5.011 Unseen face of polypharmacy in Alzheimer's disease - a focus on drug-drug interactions by M. Vrabie; V. Marinescu (S159-S160).
P.6.001 Long-term effects of pre-mating morphine exposure on maternal behaviour differ from the effects of acute morphine administration by Y. Dobryakova; I.Y. Shamakina; V.A. Dubynin (S160).
P.7.005 BDNF gene polymorphism and Wisconsin Card Sorting Test in children with ADHD and healthy controls by A. Slopien; M. Dmitrzak-Weglarz; A.R. Borkowska; F. Rybakowski; M. Witkowska; J. Hauser; A. Rajewski (S171-S172).
P.8.001 Investigation of patients' satisfaction with treatment in a mental hospital by N.V. Semenova; A.S. Kisselev (S172).
P.7.004 Cognitive and psychological problems in patients with cerebral palsy and epilepsy by P. Ignjatovic; N. Jovic (S171).
P.7.003 Acute hypoxia, modelled in early pregnancy, causes transgenerational effects on child neurodevelopment by A.V. Graf; T.Y. Dunaeva; L.K. Trofimova; M.V. Maslova; A.S. Maklakova; Y.A.V. Krushinskaya; N.A. Sokolova (S170).
P.7.001 Cognitive functions at 6 years of age after fetal exposure to antiepileptic drugs used in mothers with juvenile myoclonic epilepsy by N. Jovic; M. Knezevic-Pogancev; M.P. Ignjatovic (S169).
P.7.002 Elevated level of homocysteine in children and adolescents with psychotic and mood disorders by L. Kevere; S. Purvina; D. Bauze; M. Zeibarts; A. Rizevs; S. Jelisejevs; M. Caune; I. Purvins; R. Andrezina (S169-S170).
P.8.002 Hydrolysis of 1-methyl-5-phenyl-3-acetoxy-7-bromo-1,2-dihydro-3H-1,4-benzodiazepine-2-one with the help of pig liver microsomes by E.A. Shesterenko; I.I. Romanovska; O.V. Sevastyanov; S.A. Andronati; V.I. Pavlovsky; T.I. Yurpalova; E.A. Semenishina (S172-S173).
P.8.003 Effects of chronic maternal deprivation in white rats and their correction by administration of the ACTH(4–10) analogue semax by E.A. Sebentsova; M.A. Volodina; D.M. Manchenko; L.A. Andreeva; N.G. Levitskaya; N.F. Myasoedov (S173-S174).
Author Index (S177-S179).
Keyword Index (S181-S182).
P.8.007 The biotechnological production of potential neuroprotectants: oligo-3-hydroxybutyrates by A.P. Bonartsev; V.V. Voinova; T.K. Mahina; V.L. Myshkina; G.A. Bonartseva (S175-S176).
P.8.006 Effectiveness of idebenone therapy in Leber's hereditary optic neuropathy by J. Jancic (S175).
P.8.004 A novel active small mimetic of brain-derived neurotrophic factor: bis-(N-monosuccinyl-seryl-lysine) hexamethylenediamide by A.V. Tarasiuk; I.O. Logvinov; P.Y. Povarnina; T.A. Antipova; T.A. Gudasheva (S174).
P.8.005 Alexithymia in oncological patients: the role of hemoglobin, malignancy type and tumor staging by A. Messina; A.M. Fogliani (S174-S175).
P.6.016 Is use of caffeinated energy drinks associated with higher levels of tobacco, alcohol and other drug use in American students? by L. Hull; P.M. Dillon; M.M. O'Connell; P. Chitnavis; D.S. Svikis (S168-S169).
P.6.015 New cholecyctokinin-4 retroanalog and dipeptide analog of neurotensin as opiate dependence correctors: an experimental study by M.A. Konstantinopolsky; I.V. Chernjakova; T.A. Gudasheva (S168).
P.6.006 Molecular genetic markers of the duration of therapeutic remission in patients with alcohol dependence by A. Kibitov; E. Voskoboeva; N. Chuprova (S163).
P.6.007 Effect of L-glutamine and its dipeptides on the level of voluntary alcohol consumption in rats by P.S. Pronko; A.H. Slyahtun; V.I. Satanovskaya; T.I. Khomich; A.V. Gaishmanova (S163-S164).
P.6.005 Comparative study of the abuse potential of the kappa-opoioid agonist RU-1203 by O. Grechko; N. Eliseeva; A. Spasov; V. Anisimova (S162-S163).
P.6.004 Modulation of rewarding effects of psychotropic drugs by GABA and dopamine mechanisms from the bed nucleus of the stria terminalis by P. Shabanov; A. Lebedev; M. Sheveleva (S161-S162).
P.6.002 Comparative characteristics of neurocognitive functioning in patients with different types of abuse by N. Bushara; E. Krupitsky; E. Zvartau; E. Verbitskaya; V. Erogova; M. Tsoy (S160-S161).
P.6.003 Psychiatric co-morbidity and suicidality among methamphetamine dependent patients who seek treatment in Malaysia by A. Hatim; S. Mas Ayu; H. Habil; M. Mustafa; J. Gill; R. Rusdi; A. Amer Siddiq (S161).
P.6.008 Neuropeptide in treatment of alcoholism: effect on psychological functions and lymphocyte apoptosis by S. Ivanova; E. Zhernova; A. Mandel; N. Bokhan (S164).
P.6.009 Influence of olfactory bulbectomy on extinction and drug-seeking behaviour in rats exposed to intravenous cocaine self-administration by M. Filip; M. Bialko; K. Wydra; K. Machowska; E. Nowak; A. Suder (S164-S165).
P.6.013 Polysubstance use among HIV-infected drinkers in Russia by E. Blokhina; E. Krupitsky; D. Cheng; A. Raj; A. Walley; C. Bridden; J. Samet; S. Coleman; C. Chaisson (S167).
P.6.014 Effect of mitochondrial antioxidant SKQ-1 on the behaviour of albino rats after acute ethanol intoxication by E.V. Efimova; E.A. Kushnir; S.N. Kalabushev; M.L. Lovat (S167-S168).
P.6.012 Analysis of the impact of different forms of naltrexone on the syndrome of anhedonia and depression among heroin addicts by A. Tiurina; E. Krupitsky; E. Blokhina; N. Bushara; V. Palatkin; E. Zvartay; A. Burakov; D. Masalov; E. Verbitskaya; G. Woody (S166).
P.6.011 Pharmacological profile of the nicotinic receptor partial agonist cytisine: effects on maintenance and relapse to nicotine seeking by E. Radchenko; O. Dravolina; A. Bespalov (S165-S166).
P.6.010 Influence of naltrexone and acamprosate on the sensitivity of cerebral cortical neurons to ethanol. Electrophysiological study by S.N. Kozhechkin (S165).
P.3.003 New standardised clinico-functional criteria for therapeutic remission in schizophrenia: description and validation by A. Potapov; S. Mosolov; A. Shapharenko; A. Kostukova (S143).
P.3.002 Clebopride, an antagonist of dopamine type 2 receptors, in low doses improves learning with positive reinforcement by A.V. Malyshev; A.M. Zakharov; V.A. Dubynin; K.Y. Sarkisova (S142-S143).
P.1.005 Effect of estradiol on pain behaviour in two models of chronic pain in rats by E. Shekunova; A. Malyshkin; V. Kashkin (S119).
P.1.006 No association between promoter polymorphism of the MAOA gene and Alzheimer's disease by A. Juhasz; A. Feher; A. Rimanoczy; M. Galfi; J. Kalman; Z. Janka (S119-S120).
P.1.004 PLA2G4A and PTGS2 gene polymorphisms in schizophrenia by A. Feher; A. Juhasz; A. Rimanoczy; M. Galfi; G. Szekeres; Z. Janka (S118-S119).
P.1.003 Influence of naloxone administration on the maternal behaviour in sensitised rat dams by K.K. Tanaeva; Y.V. Dobryakova; V.A. Dubynin; A.A. Kamensky (S118).
P.1.001 The effect of glutamate antibodies on the memory of rats with experimental ischemic damage to the prefrontal cortex by G. Romanova; T. Davydova; F. Shakova; Y.U. Kvashennikova (S117).
P.1.002 Memory-stimulating effect of dehydroepiandrosterone: involvement of dopaminergic receptor systems by J. Fedotova; N. Ordayn (S117-S118).
P.1.007 Protective effect of the antiparkinsonian drug hemantane in an MPTP model using C57BL/6 mice by A. Nepoklonov; I. Kapitsa; T. Voronina; E. Valdman (S120).
P.1.009 Effects of the novel antiparkinsonian drug hemantane on brain bioelectric activity in mice with parkinsonian syndrome by I. Kapitsa; L.N. Nerobkova; K.B. Kurakhmaeva; I.I. Kokschenev; A.V. Nepoklonov; E.A. Valdman; T.A. Voronina (S120-S121).
P.1.014 Vasopressin 1b receptor polymorphism is associated with bipolar disorder by A. Szczepankiewicz; A. Leszczynska-Rodziewicz; J. Pawlak; M. Dmitrzak-Weglarz; M. Skibinska; M. Wilkosc; J. Twarowska-Hauser (S123-S124).
P.1.015 Cerebrovascular effects of mexidol in conditions of separate and combined vascular pathology of brain and heart by A. Gnezdilova; T. Ganshina; R. Mirzoyan (S124).
P.1.013 Association between suicidal behaviour and genes of serotonergic system in affective disorders by J. Pawlak; M. Dmitrzak-Weglarz; M. Skibinska; A. Szczepankiewicz; A. Leszczynska-Rodziewicz; P. Czerski; D. Zaremba; J. Hauser (S123).
P.1.012 The main proinflammatory cytokines in neuroimmune interactions by L. Kovalenko; A.V. Tallerova; S.V. Alekseeva; A.D. Durnev; S.B. Seredenin (S122-S123).
P.1.010 Gender-dependent effects of prolonged maternal deprivation and their correction by an analogue of adrenocorticotropic hormone (4–10) by M.A. Volodina; E.A. Sebentsova; N.Y.U. Glazova; N.G. Levitskaya; A.A. Kamensky; N.F. Myasoedov (S121).
P.1.011 Behavioural characterisation of magnesium effects in rats by J. Samardzic; K. Savic; D. Baltezarevic; R. Matunovic; M. Obradovic; D.I. Obradovic (S122).
S.4.05 Suicide prevention in patients with mood disorder by Z. Rihmer (S115-S116).
S.4.02 ADHD and bipolar disorder in children and adolescents by C. Moreno (S114-S115).
S.1.05 Psychopharmacological strategy in the treatment of drug dependence by M. Vinnikova; S.O. Mokhnachev (S106-S107).
S.2.03 Reasons for schizophrenia patients to refuse long-term use of antipsychotics by A. Avedisova; V.I. Borodin; D.V. Yastrebov; G.K. Dashkina (S108).
S.1.04 How neuroadaptation may preclude effective pharmacotherapy for cocaine dependence by F. Noble; N. Marie; S. Puig; N. Benturquia; C. Marie-Claire (S106).
S.1.03 Nicotine-opioid interactions: in vitro and in vivo studies by R.K. Tuominen; R. Talka; T. Kivinummi; J.S. Pakkanen; S. Nuutinen; L. Ahtee; T.P. Piepponen; P.T. Männistö; O. Salminen (S105-S106).
S.1.01 The opioid system and protracted abstinence to drugs of abuse by K. Befort (S103-S104).
S.1.02 Naltrexone for opiate dependence: oral, implantable, and injectable by E. Krupitsky (S104-S105).
S.2.04 Adherence to treatment in bipolar disorders by A. Gonzalez-Pinto; S. Ruiz De Azua (S108-S109).
S.2.05 Psychoeducation and shared decision making as a way to reduce non-compliance in mental disorders by S. Leucht (S109-S110).
S.3.04 Phenotype of stress response and effects of psychotropic drugs by S. Seredenin (S113).
S.3.05 Low positive affect, anxiety and depression by J. Harro; D. Matrov; T. Mällo; K. Raudkivi; E. Le Maitre; T Hökfelt (S113-S114).
S.3.03 Inter-individual differences in impulsivity and underlying neurobiology by J.W. Dalley (S112-S113).
S.3.02 Depression in females: difficulties in modelling and pharmacological studies by D. Avgustinovich; I. Kovalenko; G. Vishnivetskaya; M. Fomina (S111-S112).
S.3.01 Biomarkers for anxiety disorders: proteomic and systems biology approaches by C.W. Turck; R. Landgraf; M.D. Filiou; Y. Zhang; C. Webhofer; S. Reckow; P. Gormanns; C. Ditzen; G. Maccarrone; J. Varadarajulu (S110-S111).
P.1.016 Antiserotoninergic and cerebrovascular effects of combination of tropoxin and mexidol by A. Gorbunov; T. Ganshina; R. Mirzoyan (S124-S125).
P.1.017 Chronic stress-induced impairment of memory in rats can be prevented by parallel administration of cod liver oil by J. Braszko; E. Trofimiuk; A. Kulakowska (S125).
P.2.001 The presence and clinical implications of comorbid depressive disorder in women with epilepsy by K. Todorova (S136-S137).
P.2.002 Trends in depression diagnoses and antidepressants consumption in Lithuania in 2004–2009 by L. Kavaliauskiene; R. Peciura; V. Adomaitiene (S137).
P.1.036 Neurophysiological markers of cognitive disorders and 1H-magnetic resonance spectroscopy in dorsolateral prefrontal cortex of first-episode patients by I. Lebedeva; N.A. Semenova; S.V. Sidorin; V.G. Kaleda; A.N. Barkhatova; A.V. Petriakin; T.A. Akhadov (S136).
P.1.035 Antinociceptive, anti-inflammatory and gastroprotective effects of CysLT1 receptor blockers in rats by I. Marusov; M. Pchelintsev; Y. Ignatov (S135-S136).
P.1.033 Experimental pharmacokinetics and metabolism of a new potential antipsychotic by S.S. Boyko; V.P. Zherdev; R.U. Ostrovskaya; T.A. Gudasheva; N.V. Mesonznic; D.V. Bastrygin; E.V. Ivannikova (S134-S135).
P.1.034 Self reported traffic violations and driving errors are associated with markers of the serotonin system by D. Eensoo; K. Laas; M. Paaver; M. Vaht; J. Harro (S135).
P.2.003 Cognitive functioning in depressed patients treated with specific serotonin reuptake inhibitors and tricyclic antidepressants by C. Pânzaru; L. Tilea (S137-S138).
P.2.004 Psychopharmacological treatment may affect the efficacy of antiviral treatment in patients with chronic hepatitis C by W. Drozdz; D. Dybowska; D. Kozielewicz; W. Halota; A. Borkowska (S138-S139).
P.2.009 Analysis of CYP2D6*4 and 5-HTTLPR polymorphisms in a sample of North Bulgarian outpatients with depression and antidepressant treatment by D. Pendicheva; R. Kaneva; P. Hristova; A. Pandurska; I. Duhlenski; R. Marev (S141).
P.3.001 NMDA receptor co-determines vulnerability to develop dyskinesia in Huntington's Disease and levodopa-induced dyskinesia but not tardive dyskinesia by A.J.M. Loonen; S.A. Ivanova; P. Pechlivanoglou; E. Rudikov; I. Zhukova; A.F.Y. Al Hadithy; V. Alifirova; J.R.B.J. Brouwers; A. Semke; B. Wilffert (S142).
P.2.008 Treatment of bipolar disorder with somatic comorbidities - an overview of drug-drug interactions by V. Marinescu; M. Vrabie (S140-S141).
P.2.007 Assessment of memory and learning of lithium-treated euthymic bipolar patients by A. Suwalska; K. Jaracz; K. Gorna; G. Liczbinska; M. Sobieska; U. Baron; W. Palys; K. Golebiewska; D. Lojko; J.K. Rybakowski (S140).
P.2.005 Individual sensitivity of white rats to selective stimulation of neurotransmitter systems by G. Frolova (S139).
P.2.006 The effects of ZP-122 on prolyl endopeptidase activity in the brain structures of C57BL/6 and Balb/C mice after Porsolt test by I.A. Shipilov; K.N. Koliasnikova; V.B. Narkevich; V.F. Pozdnev; G.A. Nazarova; N.N. Zolotov (S139-S140).
P.1.032 The impact of psychological stress factors and cortisol on prenatal anxiety and depression by P. Salacz; S. Valent; J. Haller (S134).
P.1.031 Changes in [3H]domperidone binding in rat brains after chronic mild stress by D. Zurawek; M. Gaska; A. Faron-Gorecka; M. Kusmider; P. Gruca; M. Papp; M. Dziedzicka-Wasylewska (S133).
P.1.022 Effects of enoxifol on central neurotransmission by I.I. Goryagin; I.A. Tregubova; V.A. Kosolapov; A.A. Spasov; V.A. Anisimova (S128).
P.1.023 Circulatory shock as the physiological basis of delirium tremens by T. Galankin; L.N. Galankin (S128-S129).
P.1.021 Different influence of dopaminergic system genes on working memory in healthy subjects by M. Tomaszewska; A. Borkowska (S127-S128).
P.1.020 Influence of melatonin on blood flow in cerebral cortex under conditions of global transient ischemia by D. Maslennikov; T.S. Ganshina; R.S. Mirzoyan (S127).
P.1.018 Comparative study of the effects of afobazol and its main metabolite on learning and memory processes in a model of hemorrhagic stroke by V. Krayneva; A.V. Fedorenko (S126).
P.1.019 Neuroprotective properties of a low molecular weight dipeptide analogue of BDNF -GSB-106 in cell culture by I.O. Logvinov; T.A. Antipova; A.T. Tarasiuk; T.A. Gudasheva (S126-S127).
P.1.024 Effect of chirality on the analgesic action of the C-terminal dermorphin fragment Tyr-Pro-Ser-NH2 by L. Guzevatykh; N. Glotov; T. Voronina; T. Emelyanova; L. Andreeva; N. Myasoedov (S129).
P.1.025 BDNF gene and personality traits in anorexia nervosa patients and healthy subjects by M. Dmitrzak-Weglarz; M. Skibinska; A. Szczepankiewicz; J. Hauser; A. Slopien; F. Rybakowski; A. Rajewski; M. Maciukiewicz (S129-S130).
P.1.029 Alterations in somatostatin binding sites in brains of rats subjected to chronic mild stress by M. Kusmider; A. Faron Górecka; D. Zurawek; M. Gaska; P. Gruca; M. Papp; M. Dziedzicka-Wasylewska (S132).
P.1.030 The role of environmental effects in the serotonergic and adrenergic mediated neuro-endocrine-behavioural response by Wistar rats by M. Galfi; G. Nagyeri; Z. Valkusz; M. Radacs; T. Ocsko; P. Hausinger; M. Laszlo; A. Laszlo; A. Juhasz; J. Julesz (S132-S133).
P.1.028 Serum levels of somatostatin-28 and its binding sites in medial habenular nucleus differentiate rats responding and non responding to chronic mild stress by A. Faron-Górecka; M. Kusmider; D. Zurawek; M. Gaska; P. Gruca; M. Papp; M. Dziedzicka-Wasylewska (S131-S132).
P.1.027 Changes of gene expression in the pituitary reflect different stress responses in rats exposed to chronic stress by M. Gaska; A. Faron-Gorecka; M. Kusmider; J. Solich; P. Gruca; M. Papp; M. Dziedzicka-Wasylewska (S131).
P.1.026 Low dose nicotine improves 6-OHDA-induced impairment of memory, oxidative stress and food reward in nucleus accumbens by A. Ciobica; L. Hritcu; M. Padurariu; Z. Olteanu; V. Bild (S130-S131).
K.2 Glutamatergic systems and brain diseases by A. Bespalov (S101).